199 related articles for article (PubMed ID: 10336801)
21. Adapting by calibration the sample size of a phase III trial on the basis of phase II data.
Martini DD
Pharm Stat; 2011; 10(2):89-95. PubMed ID: 20140977
[TBL] [Abstract][Full Text] [Related]
22. Designing phase II studies in cancer with time-to-event endpoints.
Owzar K; Jung SH
Clin Trials; 2008; 5(3):209-21. PubMed ID: 18559409
[TBL] [Abstract][Full Text] [Related]
23. On the importance of accounting for competing risks in pediatric brain cancer: II. Regression modeling and sample size.
Tai BC; Grundy R; Machin D
Int J Radiat Oncol Biol Phys; 2011 Mar; 79(4):1139-46. PubMed ID: 20472355
[TBL] [Abstract][Full Text] [Related]
24. Estimating sample size for a randomized clinical trial of lung cancer screening.
Obuchowski NA
Contemp Clin Trials; 2008 Jul; 29(4):466-77. PubMed ID: 18088564
[TBL] [Abstract][Full Text] [Related]
25. Robust Bayesian sample size determination in clinical trials.
Brutti P; De Santis F; Gubbiotti S
Stat Med; 2008 Jun; 27(13):2290-306. PubMed ID: 18205170
[TBL] [Abstract][Full Text] [Related]
26. Balanced two-stage designs for phase II clinical trials.
Ye F; Shyr Y
Clin Trials; 2007; 4(5):514-24. PubMed ID: 17942467
[TBL] [Abstract][Full Text] [Related]
27. Sequential designs for phase III clinical trials incorporating treatment selection.
Stallard N; Todd S
Stat Med; 2003 Mar; 22(5):689-703. PubMed ID: 12587100
[TBL] [Abstract][Full Text] [Related]
28. Adaptive increase in sample size when interim results are promising: a practical guide with examples.
Mehta CR; Pocock SJ
Stat Med; 2011 Dec; 30(28):3267-84. PubMed ID: 22105690
[TBL] [Abstract][Full Text] [Related]
29. Randomized phase II designs in cancer clinical trials: current status and future directions.
Lee JJ; Feng L
J Clin Oncol; 2005 Jul; 23(19):4450-7. PubMed ID: 15994154
[TBL] [Abstract][Full Text] [Related]
30. Calculation of sample size for stroke trials assessing functional outcome: comparison of binary and ordinal approaches.
Optimising Analysis of Stroke Trials Collaboration
Int J Stroke; 2008 May; 3(2):78-84. PubMed ID: 18705999
[TBL] [Abstract][Full Text] [Related]
31. Re: Bacillus Calmette-Guerin versus epirubicin for primary, secondary or concurrent carcinoma in situ of the bladder: results of a European Organization for the Research and Treatment of Cancer-Genito-Urinary Group Phase III Trial (30906).
Mehraban D; Esfahani F
J Urol; 2005 Sep; 174(3):1151; author reply 1151. PubMed ID: 16094088
[No Abstract] [Full Text] [Related]
32. Sample Size Calculation in Oncology Trials: Quality of Reporting and Implications for Clinical Cancer Research.
Bariani GM; de Celis Ferrari AC; Precivale M; Arai R; Saad ED; Riechelmann RP
Am J Clin Oncol; 2015 Dec; 38(6):570-4. PubMed ID: 24401665
[TBL] [Abstract][Full Text] [Related]
33. Sample size determination for comparing several survival curves with unequal allocations.
Halabi S; Singh B
Stat Med; 2004 Jun; 23(11):1793-815. PubMed ID: 15160409
[TBL] [Abstract][Full Text] [Related]
34. Sample size determination for assessing equivalence based on proportion ratio under a randomized trial with non-compliance and missing outcomes.
Lui KJ; Chang KC
Stat Med; 2008 Jan; 27(1):47-67. PubMed ID: 17708514
[TBL] [Abstract][Full Text] [Related]
35. The clinical significance of statistical significance.
Kane RC
Oncologist; 2008 Nov; 13(11):1129-33. PubMed ID: 18984874
[TBL] [Abstract][Full Text] [Related]
36. Sample size re-estimation in group-sequential response-adaptive clinical trials.
Morgan CC
Stat Med; 2003 Dec; 22(24):3843-57. PubMed ID: 14673942
[TBL] [Abstract][Full Text] [Related]
37. A note on the power of Fisher's least significant difference procedure.
Meier U
Pharm Stat; 2006; 5(4):253-63. PubMed ID: 17128424
[TBL] [Abstract][Full Text] [Related]
38. Applying sensitivity analyses to overall survival in cancer clinical trials.
Wolff SN
J Clin Oncol; 2010 Jul; 28(19):e323; author reply e324. PubMed ID: 20516448
[No Abstract] [Full Text] [Related]
39. Continuous toxicity monitoring in phase II trials in oncology.
Ivanova A; Qaqish BF; Schell MJ
Biometrics; 2005 Jun; 61(2):540-5. PubMed ID: 16011702
[TBL] [Abstract][Full Text] [Related]
40. Power of 'phase 0' chronobiologic trials at different signal-to-noise ratios and sample sizes.
Bingham C; Cornélissen G; Halberg F
Chronobiologia; 1993; 20(3-4):179-90. PubMed ID: 8131667
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
